REFERENCES
- Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578–1583.
- Bantis C, Ivens K, Kreusser W, Koch M, Klein-Vehne N, Grabensee B, Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol. 2004;24(2):258–267.
- Briet M, Schiffrin EL. Aldosterone: Effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–273.
- Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension. 2005;46(3):584–590.
- Brand E, Chatelain N, Mulatero P, Fery I, Curnow K,, Jeunemaitre X, Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension. 1998; 32(2):198–204.
- White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res. 1995;21(1–2):437–442.
- Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens. 1998; 11(7):856–860.
- Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW, Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation. 1999;99(17):2255–2260.
- Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension. 1999;34(3):423–429.
- Hautanena A, Lankinen L, Kupari M, Janne OA, Adlercreutz H, Nikkila H, Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med. 1998;244(1):11–18.
- Tamaki S, Iwai N, Tsujita Y, Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension. 1999;33(1 Pt 2): 266–270.
- Song J, Narita I, Goto S, Saito N, Omori K, Sato F, Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. J Med Genet. 2003;40(5):372–376.
- Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol. 2009;296(6):F1323–F1333.
- Lai L, Chen J, Hao CM, Lin S, Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun. 2006;348(1):70–75.
- Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol. 2008;19(2):298–309.
- Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG, Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63(5): 1791–1800.
- Kretzler M, Koeppen-Hagemann I, Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch. 1994;425(2):181–193.
- Gullulu M, Akdag I, Kahvecioglu S, Filiz G, Savci V. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail. 2006;28(6):509–514.
- Asai M, Monkawa T, Marumo T, Fukuda S, Tsuji M, Yoshino J, Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res. 2004;27(12):971–978.
- Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70(12):2116–2123.
- Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940–951.